Name | 9-Isopropyl-N2-[4-(4-methyl-1-piperazinyl)phenyl]-N8-(3-pyridinyl)-9H-purine-2,8-diamine |
---|---|
Synonyms |
9H-Purine-2,8-diamine, 9-(1-methylethyl)-N2-[4-(4-methyl-1-piperazinyl)phenyl]-N8-3-pyridinyl-
9-Isopropyl-N2-[4-(4-methyl-1-piperazinyl)phenyl]-N8-(3-pyridinyl)-9H-purine-2,8-diamine MFCD30471083 |
Description | Ruserontinib (SKLB1028) is an orally active multikinase inhibitor of EGFR, FLT3 and Abl, with an IC50 value of 55 nM for human FLT3, and has antitumor activity[1]. |
---|---|
Related Catalog | |
In Vitro | Ruserontinib (SKLB1028)可以显著抑制表达 FLT3-ITD的 mf4 -11 细胞的生长,IC50值为 0.002 μM,抑制表达 wt-FLT3 的 RS4-11 细胞增殖的 IC50值为 0.790 μM,抑制稳定表达人 FLT3ITD 的 Ba/F3 细胞生长的IC50值为 0.01 μM,抑制表达 Bcr-Abl 突变体的 K562 细胞生长的 IC50为0.190 μM[1]。 Ruserontinib (SKLB1028) (0-100 nM, 20 h)导致 MV4-11 细胞的 pro-caspase-3水平呈剂量依赖性下降,而被切割的 caspase-3 片段水平呈剂量依赖性增加,并且可以以剂量依赖的方式抑制 STAT5 和 Erk1/2 的磷酸化[1]。 |
In Vivo | Ruserontinib (SKLB1028)(5-70 mg/kg,每天口服一次,18 天)在 MV4-11 和 K562 异种移植 NOD-SCID 模型中具有抗肿瘤作用[1]。 Animal Model: MV4-11 and K562 xenograft NOD-SCID models[1] Dosage: 5, 10, 20 mg/kg,70 mg/kg Administration: orally once daily, 18 days Result: Prevented tumor growth at a dose of 5 mg/kg, and caused rapid and complete tumor regression in both groups of mice at a dose of 10 or 20 mg/kg. Significantly inhibited the proliferation and induced apoptosis of MV4-11 and K562 cells at a dose of 70 mg/kg. |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 671.8±65.0 °C at 760 mmHg |
Molecular Formula | C24H29N9 |
Molecular Weight | 443.55 |
Flash Point | 360.1±34.3 °C |
Exact Mass | 443.254578 |
LogP | 2.03 |
Vapour Pressure | 0.0±2.1 mmHg at 25°C |
Index of Refraction | 1.707 |
Storage condition | 2-8°C |